Purple Biotech Ltd. (PPBT) has disclosed a new risk, in the Trade Secrets category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The analyst notes that Purple Biotech Ltd. faces meaningful exposure if patent terms expire before or soon after its products reach the market, given lengthy development and regulatory timelines. Once key patents lapse or if extensions like Hatch–Waxman or SPCs are unavailable or shortened, the company could rapidly lose exclusivity and face intense generic competition, eroding pricing power and returns on R&D investment.
Overall, Wall Street has a Moderate Buy consensus rating on PPBT stock based on 1 Buy.
To learn more about Purple Biotech Ltd.’s risk factors, click here.